CD7-targeting humanized antibody and use thereof
The present invention provides a CD7-targeting humanized antibody, and a multispecific antibody, chimeric antigen receptor, antibody conjugate, pharmaceutical composition, and kit comprising the CD7-targeting humanized antibody, and a use thereof in the diagnosis/treatment/prevention of diseases associated with CD7 expression.
1 . An anti-CD7 humanized antibody comprising a light chain variable region and a heavy chain variable region, wherein the light chain variable region comprises CDR-L1 as set forth in SEQ ID NO: 1, CDR-L2 as set forth in SEQ ID NO: 2 and CDR-L3 as set forth in SEQ ID NO: 3, the heavy chain variable region comprises CDR-H1 as set forth in SEQ ID NO: 4, CDR-H2 as set forth in SEQ ID NO: 5 and CDR-H3 as set forth in SEQ ID NO: 6, and the light chain variable region has at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 8, 11, 14 and 17, and the heavy chain variable region has at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 9, 12, 15 and 18.
2 . The humanized antibody according to claim 1 , wherein the anti-CD7 humanized antibody comprises a light chain variable region-consisting of SEQ ID NO: 17 and a heavy chain variable region consisting of SEQ ID NO: 18.
3 . The humanized antibody according to claim 1 , wherein the anti-CD7 humanized antibody has an amino acid sequence selected from the group consisting of SEQ ID NOs: 10, 13, 16 and 19.
4 . A multispecific antibody comprising the humanized antibody according to claim 1 and one or more second antibodies or antigen-binding portions thereof that specifically bind to antigens different from CD7.
5 . The multispecific antibody according to claim 4 , wherein the second antibody or antigen binding portion thereof is selected from the group consisting of a full-length antibody, Fab, Fab′, (Fab′)2, Fv, scFv, scFv-scFv, a minibody, a diabody or sdAb.
6 . An antibody conjugate comprising the humanized antibody according to claim 1 , and a second functional structure, wherein the second functional structure is selected from the group consisting of Fc, a radioisotope, a structure moiety for extending half-life, a detectable marker and a drug.
7 . A detection kit, comprising the humanized antibody according to claim 1 .
8 . A pharmaceutical composition, comprising the humanized antibody according to claim 1 , and one or more pharmaceutically acceptable excipients.
9 . The humanized antibody according to claim 1 , wherein the anti-CD7 humanized antibody comprises:
a light chain variable region as set forth in SEQ ID NO: 8 and a heavy chain variable region as set forth in SEQ ID NO: 9;
a light chain variable region as set forth in SEQ ID NO: 11 and a heavy chain variable region as set forth in SEQ ID NO: 12; or
a light chain variable region as set forth in SEQ ID NO: 14 and a heavy chain variable region as set forth in SEQ ID NO: 15.